



October 16, 2023

**BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

Vide letter dated September 11, 2023, we had informed the Exchange as regards Lupin Limited ('the Company') having planned to enter into a Business Transfer Agreement ('BTA') with Lupin Manufacturing Solutions Limited ('LMSL'), wholly owned subsidiary of the Company, to carve out two Active Pharmaceutical Ingredients manufacturing sites situate at Dabhasa and Visakhapatnam and select R&D operations, including fermentation, at Lupin Research Park, Pune.

We are now pleased to inform you that today i.e. October 16, 2023, the Company has entered into a BTA with LMSL in connection with the carve out.

This may kindly be considered as disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS -11973)**